Schurch, B., de Seze, M., Denys, P., et al. (2005) Botulinum Toxin Type A Is a Safe and Effective Treatment for Neurogenic Urinary Incontinence: Results of a Single Treatment, Randomized, Placebo Controlled 6-Month Study. The Journal of Urology, 174, 196-200.
https://doi.org/10.1097/01.ju.0000162035.73977.1c

has been cited by the following article:

• TITLE: Therapeutic Outcome of Botulinum Toxin Type A for Patients with Low Bladder Compliance Secondary to Spinal Cord Injury

  AUTHORS: H. Chen, M. P. Huang, T. H. Huang, C. H. Jiang, J. W. Zeng, L. L. Zhou, Q. L. Liu, Q. Q. Li, X. Y. Yang

  KEYWORDS: Botulinum Toxin Type A, Low Bladder Compliance, Spinal Cord Injury

  JOURNAL NAME: Open Journal of Urology, Vol.7 No.11, November 14, 2017

  ABSTRACT: Objective: To evaluate the efficacy and safety of botulinum toxin type A (BTX-A) in treating patients with low bladder compliance (BC) secondary to spinal cord injury (SCI). Methods: From 2011 to 2016, we retrospected patients who received BTX-A injections for LBC secondary to SCI. The primary outcomes were urodynamic parameters including maximum detrusor pressure (Pdetmax), bladder compliance (BC). Related adverse events were recorded. Results: 72 SCI patients were selected (62 males, 10 females, age range 18 - 52 years; mean age 28.5 years). 12 weeks after BTX-A injection, Pdetmax decreased from 51.02 cmH2O to 28.31 cmH2O. BC increased from 3.64 ml/cmH2O to 10.08 ml/cmH2O. 12 patients had mild transient haematuria for 1 - 2 days. Conclusion: Intradetrusor BTX-A injection was effective and safe for patients with low BC secondary to SCI.